Dagmar Rosa-Björkeson is the senior vice president, new product commercialization at Mallinckrodt Pharmaceuticals. She has responsibility for leading a team focused on shaping Mallinckrodt’s development programs and supporting commercialization efforts to ensure high quality product launches that benefit the patient, customer and company needs. Ms. Rosa-Björkeson is a member of Mallinckrodt’s commercial leadership team. Prior to joining Mallinckrodt, Ms. Rosa-Björkeson served as a biotech/biopharmaceuticals and therapeutics leader for Fortune 500 companies such as Baxalta and Novartis, start-ups and agencies. Throughout her career, Ms. Rosa-Björkeson’s leadership has been recognized with several awards and she has been featured in numerous articles. She is a member of Deirdre’s House and the New Jersey City University Foundation’s board of directors. Ms. Rosa-Björkeson holds a bachelor’s and master’s degree in chemistry and an MBA in marketing from the University of Texas-Austin. She is fluent in English and Spanish with basic knowledge of French and Swedish.